What are the indications for evantumumab? Are there generic drugs available?

Amivantamab is a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and the MET receptor. It is mainly used to treat patients with non-small cell lung cancer (NSCLC), especially those carrying EGFR exon 20 insertion mutations. This drug effectively prevents the growth and spread of tumor cells by inhibiting the EGFR and MET signaling pathways.

The indications for evantumumab include: First, it is used in combination with Lazertinib (Lazertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have EGFR exon 19 deletions or exon 21 L858R substitution mutations. These mutations are common driver mutations in non-small cell lung cancer, and treatments targeting these mutations can significantly improve patient response and survival.

Secondly, evantumumab is also used in combination with carboplatin and pemetrexed for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This therapy provides a new treatment option for patients with EGFR exon 20 insertion mutations, which often lead to resistance to traditional EGFR-targeted therapies. Finally, evantumumab is indicated as monotherapy for those patients with locally advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation, particularly if their disease has progressed after or during platinum-based chemotherapy.

Although evantumumab has shown good efficacy in clinical treatment, especially for refractory lung cancer patients with EGFR mutations and MET amplification, there are currently no generic drugs of this drug on the market worldwide. The innovative mechanism of evantumumab makes it one of the key drugs for the treatment of refractory non-small cell lung cancer. However, due to its research and development complexity and patent protection, the development of generic drugs still faces greater challenges. As the patent period expires, generic drugs may appear in the future, but currently patients can only use the original drugs.

Reference materials:https://www.rybrevant.com/